When was Tris Pharma founded?

Tris Pharma was founded in 2000 and raised its 1st funding round 18 years after it was founded.

Where is Tris Pharma located?

Tris Pharma is headquartered in Monmouth Junction, United States. It is registered at Monmouth Junction, New Jersey.

Who is the current CEO of Tris Pharma?

Ketan Mehta of Tris Pharma. They have also founded 1 company.

How many employees does Tris Pharma have?

As of May 31, 2026, the latest employee count at Tris Pharma is 502.

Is Tris Pharma a funded company?

Tris Pharma is a funded company, having raised a total of $125M across 3 funding rounds to date. The company's 1st funding round was a $***** Conventional Debt round, raised on Sep 21, 2018.

When was the latest funding round of Tris Pharma?

Tris Pharma's latest funding was a $***** Grant (prize money) round on Sep 05, 2023, with participation from 1 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.1B in funding in 2026 to date.

Where does Tris Pharma rank among its competitors?

Tris Pharma ranks 147th amongst 2843 active competitors, of which 980 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Tris Pharma?

Tris Pharma's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Tris Pharma - 2026 Company Profile, Team, Funding & Competitors

Tris Pharma is a series B company based in Monmouth Junction (United States), founded in 2000 by Ketan Mehta. It operates as an Innovating transformative treatments for ADHD, pain, and CNS disorders. Tris Pharma has raised $125M in funding. The company has 2843 active competitors, including 980 funded and 707 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Innovating transformative treatments for ADHD, pain, and CNS disorders. This biopharmaceutical company focuses on developing and commercializing innovative medicines addressing unmet patient needs in neuroscience and other therapeutic categories. They utilize proprietary science and technology to create differentiated therapeutic approaches, including novel mechanisms and investigational compounds. Their commitment extends to delivering high-quality, patient-friendly therapeutics with maximum benefit. They have a robust pipeline of investigational therapies targeting ADHD, pain, addiction, and other central nervous system diseases. They are dedicated to advancing the science of pain biology and improving the lives of patients through innovation and a culture of care.

Website: www.trispharma.com/
Email ID: *****@trispharma.com
Phone Number: +1 **********
Registered Address: Monmouth Junction, New Jersey

Key Metrics

Founded Year

2000

Location

Monmouth Junction, United States

Stage

Series B

Total Funding

$125M in 3 rounds

Latest Funding Round

Grant (prize money), Sep 05, 2023, $*****

Investors

Deerfield & 1 more

Ranked

147^th among 2843 active competitors

Employee Count

502 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 562 more

View Tris Pharma's full profile

Tris Pharma is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
TRIS PHARMA, INC. CIN: 223747409 , United States, Active	Dec 26, 999	-	556 (As on Dec 31, 2024)	-
TRIS PHARMA, INC. CIN: 32059154339 , United States, Active	Dec 24, 2015	-	-	-
Tris Pharma, Inc CIN: 22-3747409 , United States, Active	Dec 31, 1999	-	441 (As on Dec 31, 2021)	-
Tris Pharma, Inc. CIN: 10251512 , United States, Active	Nov 19, 2023	-	-	-

Tris Pharma has raised a total funding of $125M over 3 rounds. Its first funding round was on Sep 21, 2018. Its latest funding round was a Grant (prize money) round on Sep 05, 2023 for $*****. 1 investor participated in its latest round. Tris Pharma has 2 institutional investors.

Here is the list of recent funding rounds of Tris Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 05, 2023	5492604	Grant (prize money)	4759184	1136681	9010047	9698979
Sep 21, 2018	9745521	Series B	8023166	4200676	5672708	Deerfield
Sep 21, 2018	3454335	Conventional Debt	6547078	3035170	1909159	Deerfield

Access funding benchmarks and valuations. Sign up today!

View details of Tris Pharma's funding rounds and investors

The founders of Tris Pharma is Ketan Mehta. Ketan Mehta is the CEO of Tris Pharma.

Here are the details of Tris Pharma's key team members:

Ketan Mehta: Founder & CEO of Tris Pharma.

View details of Tris Pharma's Founder profiles and Board Members

Tris Pharma's employee count trend

Tris Pharma has 502 employees as of May 26. Here is Tris Pharma's employee count trend over the years:

Uncover Tris Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Tris Pharma include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Tris Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
147th	Tris Pharma 2000, Monmouth Junction (United States), Series B	Innovating transformative treatments for ADHD, pain, and CNS disorders	$125M	Deerfield, NIH	61/100